Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.

Pettigrew C, Soldan A, Sloane K, Cai Q, Wang J, Wang MC, Moghekar A, Miller MI, Albert M; BIOCARD Research Team.

Neuroimage Clin. 2017 Aug 25;16:439-446. doi: 10.1016/j.nicl.2017.08.022. eCollection 2017.

2.

Alzheimer's disease CSF biomarkers: clinical indications and rational use.

Niemantsverdriet E, Valckx S, Bjerke M, Engelborghs S.

Acta Neurol Belg. 2017 Jul 27. doi: 10.1007/s13760-017-0816-5. [Epub ahead of print] Review.

3.

18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease.

Mattsson N, Schöll M, Strandberg O, Smith R, Palmqvist S, Insel PS, Hägerström D, Ohlsson T, Zetterberg H, Jögi J, Blennow K, Hansson O.

EMBO Mol Med. 2017 Sep;9(9):1212-1223. doi: 10.15252/emmm.201707809.

4.

Investigating Focal Connectivity Deficits in Alzheimer's Disease Using Directional Brain Networks Derived from Resting-State fMRI.

Zhao S, Rangaprakash D, Venkataraman A, Liang P, Deshpande G.

Front Aging Neurosci. 2017 Jul 6;9:211. doi: 10.3389/fnagi.2017.00211. eCollection 2017.

5.

Applying fluid biomarkers to Alzheimer's disease.

Zetterberg H.

Am J Physiol Cell Physiol. 2017 Jul 1;313(1):C3-C10. doi: 10.1152/ajpcell.00007.2017. Epub 2017 Apr 19. Review.

PMID:
28424166
6.

Early-Onset Alzheimer Disease.

Mendez MF.

Neurol Clin. 2017 May;35(2):263-281. doi: 10.1016/j.ncl.2017.01.005. Review.

PMID:
28410659
7.

Tau oligomers in cerebrospinal fluid in Alzheimer's disease.

Sengupta U, Portelius E, Hansson O, Farmer K, Castillo-Carranza D, Woltjer R, Zetterberg H, Galasko D, Blennow K, Kayed R.

Ann Clin Transl Neurol. 2017 Mar 1;4(4):226-235. doi: 10.1002/acn3.382. eCollection 2017 Apr.

8.

Microstructural white matter alterations in preclinical Alzheimer's disease detected using free water elimination diffusion tensor imaging.

Hoy AR, Ly M, Carlsson CM, Okonkwo OC, Zetterberg H, Blennow K, Sager MA, Asthana S, Johnson SC, Alexander AL, Bendlin BB.

PLoS One. 2017 Mar 14;12(3):e0173982. doi: 10.1371/journal.pone.0173982. eCollection 2017.

9.

Dissociating Normal Aging from Alzheimer's Disease: A View from Cognitive Neuroscience.

Toepper M.

J Alzheimers Dis. 2017;57(2):331-352. doi: 10.3233/JAD-161099.

10.

Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and Aβ42 levels.

Lattanzio F, Abu-Rumeileh S, Franceschini A, Kai H, Amore G, Poggiolini I, Rossi M, Baiardi S, McGuire L, Ladogana A, Pocchiari M, Green A, Capellari S, Parchi P.

Acta Neuropathol. 2017 Apr;133(4):559-578. doi: 10.1007/s00401-017-1683-0. Epub 2017 Feb 15.

11.

BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants.

Timmers M, Barão S, Van Broeck B, Tesseur I, Slemmon J, De Waepenaert K, Bogert J, Shaw LM, Engelborghs S, Moechars D, Mercken M, Van Nueten L, Tritsmans L, de Strooper B, Streffer JR.

J Alzheimers Dis. 2017;56(4):1437-1449. doi: 10.3233/JAD-160829.

12.

Enhancing attention in neurodegenerative diseases: current therapies and future directions.

Sharma K, Davis T, Coulthard E.

Transl Neurosci. 2016 Oct 22;7(1):98-109. doi: 10.1515/tnsci-2016-0016. eCollection 2016.

13.

Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network.

Takahashi H, Klein ZA, Bhagat SM, Kaufman AC, Kostylev MA, Ikezu T, Strittmatter SM; Alzheimer’s Disease Neuroimaging Initiative.

Acta Neuropathol. 2017 May;133(5):785-807. doi: 10.1007/s00401-017-1668-z. Epub 2017 Jan 9.

PMID:
28070672
14.

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease.

Öhrfelt A, Brinkmalm A, Dumurgier J, Brinkmalm G, Hansson O, Zetterberg H, Bouaziz-Amar E, Hugon J, Paquet C, Blennow K.

Alzheimers Res Ther. 2016 Oct 3;8(1):41.

15.

Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer's disease.

Saint-Aubert L, Almkvist O, Chiotis K, Almeida R, Wall A, Nordberg A.

Alzheimers Res Ther. 2016 Sep 29;8(1):38.

16.

Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease.

Öhrfelt A, Johansson P, Wallin A, Andreasson U, Zetterberg H, Blennow K, Svensson J.

Dement Geriatr Cogn Dis Extra. 2016 Jul 15;6(2):283-94. doi: 10.1159/000447239. eCollection 2016 May-Aug.

17.

Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.

Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P, McConathy J, Cairns NJ, Fagan AM, Morris JC, Ances BM.

JAMA Neurol. 2016 Sep 1;73(9):1070-7. doi: 10.1001/jamaneurol.2016.2078.

18.

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, Petersen RC, Scheltens P, Sperling RA, Dubois B.

Neurology. 2016 Aug 2;87(5):539-47. doi: 10.1212/WNL.0000000000002923. Epub 2016 Jul 1. Review.

19.

Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?

Del Campo Milan M, Zuroff L, Jimenez CR, Scheltens P, Teunissen CE.

Alzheimers Dement (Amst). 2015 Mar 29;1(1):75-80. doi: 10.1016/j.dadm.2014.11.008. eCollection 2015 Mar.

20.

Potential Long-Term Consequences of Concussive and Subconcussive Injury.

Huber BR, Alosco ML, Stein TD, McKee AC.

Phys Med Rehabil Clin N Am. 2016 May;27(2):503-11. doi: 10.1016/j.pmr.2015.12.007. Epub 2016 Feb 2. Review.

Supplemental Content

Support Center